Daniel Huber

Safety of the oral factor XIa inhibitor asundexian compared with apixaban in patients with atrial fibrillation (PACIFIC-AF): a multicentre, randomised, double-blind, double-dummy, dose-finding phase 2 study

Jonathan P. Piccini, Valeria Caso, Stuart J. Connolly et al. · The Lancet · 2022 · 296 citations · Full text

Thrombosis, Dose-finding Phase 2, Cardiovascular Disease +10

Determinants of ejection performance in aortic stenosis.

Daniel Huber, J Grimm, Rick Koch et al. · Circulation · 1981 · 184 citations · Full text

Heart Failure, Cardiovascular Disease, Aortic Stenosis +6

Some neonatal risk factors for adult pulmonary arterial hypertension remain unknown

Estelle Naumburg, Inge Axelsson, Daniel Huber et al. · Acta Paediatrica · 2015 · 53 citations

Risk factors for pulmonary arterial hypertension in children and young adults

Estelle Naumburg, Lars Söderström, Daniel Huber et al. · Pediatric Pulmonology · 2016 · 45 citations · Full text

Statin treatment after acute coronary syndrome: Adherence and reasons for non-adherence in a randomized controlled intervention trial

Daniel Huber, Christian Wikén, Robin Henriksson et al. · Scientific Reports · 2019 · 36 citations · Full text